Maiolino, Angelo <br/><br/>
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.  [electronic resource] 

 -  American journal of hematology  Oct 2012 
 - 948-52 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-8652 
<br/><br/><label>Standard No.: </label>10.1002/ajh.23274  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Combined Modality Therapy<br/>Cyclophosphamide--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Granulocyte Colony-Stimulating Factor--administration & dosage<br/>Humans<br/>Kaplan-Meier Estimate<br/>Maintenance Chemotherapy<br/>Male<br/>Melphalan--administration & dosage<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Peripheral Blood Stem Cell Transplantation<br/>Proportional Hazards Models<br/>Remission Induction<br/>Thalidomide--administration & dosage<br/>Transplantation, Autologous<br/>Vincristine--administration & dosage